NR4A1 and breast cancer: For instance, the systemic treatment of nonmetastatic BC typically varies based on the subtype: Hormone receptor-positive tumors generally exhibit improved outcomes with endocrine therapy, while erb-b2 receptor tyrosine kinase 2 (ERBB2)-positive tumors typically require ERBB2-targeted antibodies or small-molecule inhibitors in combination with chemotherapy.